Stay updated with breaking news from Psychiatric Practice. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Marketresearch.biz reports that Psychedelic Drugs Market size is expected to be worth around USD 5.1 Bn by 2032 from USD 2.5 Bn in 2022, growing at a CAGR of 7.6% during the forecast period from 2023 to 2032.Overview of the Psychedelic Drugs MarketThe Psychedelic Drugs Market is experiencing a renaissance, driven by...
What 10 things do you need to know before entering a job interview?
A growing body of evidence suggests that psychedelic drugs may be useful in treating various mental health conditions.
Arizona is investing $5 million to study if psychedelic mushrooms can help people with addiction, pain and PTSD.Now the Journal of Psychiatric Practice says there are challenges to defining the clinical benefits of psilocybin.The September issue of the journal covers treating depression with what are colloquially called magic mushrooms. They contain a naturally occurring
A growing body of evidence suggests that psychedelic drugs may be useful in treating various mental health conditions. However, many challenges remain in defining their clinical benefits and overcoming the complex regulatory obstacles to their use. The September issue of Journal of Psychiatric Practice presents a research review and update on therapeutic use of psychedelics – focusing on the use of psilocybin for treatment of depression. The journal is published in the Lippincott portfolio in partnership with Wolters Kluwer.